Semaglutide CAS 910463682 White Lyophilized Powder Research Grade
59 Inquiries
1415456-99-3
Pharmaceutical Grade
98%
shenzhen
rxc
20mg,30mg,10vials in one box or as your requirement
2026-09-10
peptide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceCagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. This drug is an investigational therapy that reduced body weight in a phase 2 trial when administered as monotherapy in participants without diabetes and with a BMI of at least 30 kg/m2 or at least 27 kg/m2 with hypertension or dyslipidaemia[1-2].Basic Info
-
Product Name:
Cagrilintide
Other Name:Cagrilintide;Cargliptin;Caglitide;Cagrilintide acetate;Cagrilintide peptide;Cagrilintide 5mg 10mg 15mg;Cagrilintide(Acetate form);Kagliptin
CAS No.:1415456-99-3
Molecular Weight:0
EC Number:206-141-6
Color/Form:White to off-white
Categories:
Research-
Class:
Amylin receptor (AMYR) / calcitonin receptor (CTR) agonist (long-acting amylin analog)
Status:Investigational — Phase 3 (REDEFINE program, CagriSema combination)
Mechanism:A novel long-acting, acylated amylin (islet amyloid polypeptide, IAPP) analog consisting of 38 amino acids. Cagrilintide activates the amylin receptor (AMYR) and calcitonin receptor (CTR), reducing food intake, delaying gastric emptying, and promoting satiety. Being developed as monotherapy and in fixed-dose combination with semaglutide (CagriSema) for obesity. Administered once weekly.
Activity note:Cagrilintide is a non-selective AMYR/CTR agonist. Specific EC50 values not publicly available; functional potency is comparable to native amylin at AMYR.
Source:MCE: Cagrilintide (CAS 1415456-99-3); Novo Nordisk REDEFINE program.
Clinical Development:
References-
PubChem:Literature:
MCE: Cagrilintide (CAS 1415456-99-3); ClinicalTrials.gov: REDEFINE-1 (NCT05249895); Novo Nordisk: EASD 2025 Cagrilintide data presentation
Disclaimer:Cagrilintide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials (REDEFINE program). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
peptide
-
Location:
south road and north road
-
Payment Terms:
TT against copy of documents,L/C,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
15
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2022
-
-
Inquiry History59 Inquiries
Country Product Purchase Quantity Date Posted 
United States
Retatrutid3
10 MT Aug 4, 2026
United States
Retatrutide
20 MT Jul 25, 2026
United States
Cagrilintide
10 MG Jul 13, 2026 
Peru
Cagrilintide 20MG vial
10 PCS Jul 10, 2026 
New Zealand
Cagrilintide
10 MG May 19, 2026
United States
Cagrilintide
1 G May 18, 2026
United States
Cagrilintide
20 MG May 8, 2026 
India
Cagrilintide
1 KG Apr 13, 2026
United States
Tirzepatide
50 MT Apr 2, 2026
India
CAGRILINTIDE
100 MG Mar 11, 2026
United States
Cagrilintide
500 MG Feb 16, 2026 
Ghana
carigrilintide
10 MG Feb 9, 2026
United States
Cagrilintide
20 MG Jan 13, 2026
United States
Cagrilintide
1 KG Dec 15, 2025
United States
Cagrilintide
1 KG Oct 11, 2025
United States
Cagrilintide
25 MT Aug 13, 2025 
Germany
Cagrilintide
50 G Aug 3, 2025
United States
Cagrilintide
10 MG Jul 3, 2025
United States
Cagrilintide
1 G Jun 16, 2025
United States
Cagrilintide
1 KG Apr 6, 2025 Post an enquiry for this product
